Literature DB >> 19424831

Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence supported by structural equation modeling (SEM) parameter estimates.

Eric R Braverman1, Thomas J H Chen, Thomas J Prihoda, William Sonntag, Brian Meshkin, B William Downs, Julie F Mengucci, Seth H Blum, Alison Notaro, Vanessa Arcuri, Michael Varshavskiy, Kenneth Blum.   

Abstract

A review of the literature in both animals and humans reveals that changes in sex hormone have often been associated with changes in behavioral and mental abilities. Previously published research from our laboratory, and others, provides strong evidence that P300 (latency) event-related potential (ERP), a marker of neuronal processing speed, is an accurate predictor of early memory impairment in both males and females across a wide age range. It is our hypothesis, given the vast literature on the subject, that coupling growth hormones (insulin-like growth factor-I, (IGF-I) and insulin-like growth factor binding protein 3 (IGF-BP3)), P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting. To support this hypothesis, we utilized structural equation modeling (SEM) parameter estimates to determine the relationship between aging and memory, as mediated by growth hormone (GH) levels (indirectly measured through the insulin-like growth factor system), P300 latency and TOVA, putative neurocognitive predictors tested in this study. An SEM was developed hypothesizing a causal directive path, leading from age to memory, mediated by IGF-1 and IGF-BP3, P300 latency (speed), and TOVA decrements. An increase in age was accompanied by a decrease in IGF-1 and IGF-BP3, an increase in P300 latency, a prolongation in TOVA response time, and a decrease in memory functioning. Moreover, independent of age, decreases in IGF-1 and IGF-BP3, were accompanied by increases in P300 latency, and were accompanied by increases in TOVA response time. Finally, increases in P300 latency were accompanied by decreased memory function, both directly and indirectly through mediation of TOVA response time. In summary, this is the first report utilizing SEM to reveal the finding that aging affects memory function negatively through mediation of decreased IGF-1 and IGF-BP3, and increased P300 latency (delayed attention and processing speed).

Entities:  

Year:  2007        PMID: 19424831      PMCID: PMC2267660          DOI: 10.1007/s11357-007-9030-3

Source DB:  PubMed          Journal:  Age (Dordr)        ISSN: 0161-9152


  140 in total

1.  Cortisol and dehydroepiandosterone sulfate plasma levels and their relationship to aging, cognitive function, and dementia.

Authors:  V M S de Bruin; M C M Vieira; M N M Rocha; G S B Viana
Journal:  Brain Cogn       Date:  2002-11       Impact factor: 2.310

2.  Progestins and estrogens and Alzheimer's disease.

Authors:  Hideo Honjo; Koichi Iwasa; Mitsuhiro Kawata; Shinji Fushiki; Tetsuya Hosoda; Hiroshi Tatsumi; Naochika Oida; Masaya Mihara; Yoshiichiro Hirasugi; Hiroki Yamamoto; Noriko Kikuchi; Jo Kitawaki
Journal:  J Steroid Biochem Mol Biol       Date:  2005-01-24       Impact factor: 4.292

3.  Quantitative trait loci analysis of human event-related brain potentials: P3 voltage.

Authors:  H Begleiter; B Porjesz; T Reich; H J Edenberg; A Goate; J Blangero; L Almasy; T Foroud; P Van Eerdewegh; J Polich; J Rohrbaugh; S Kuperman; L O Bauer; S J O'Connor; D B Chorlian; T K Li; P M Conneally; V Hesselbrock; J P Rice; M A Schuckit; R Cloninger; J Nurnberger; R Crowe; F E Bloom
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1998-04

Review 4.  Neuroprotective effects of female sex steroids in humans: current controversies and future directions.

Authors:  C E Gleason; B Cholerton; C M Carlsson; S C Johnson; S Asthana
Journal:  Cell Mol Life Sci       Date:  2005-02       Impact factor: 9.261

5.  DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study.

Authors:  O M Wolkowitz; J H Kramer; V I Reus; M M Costa; K Yaffe; P Walton; M Raskind; E Peskind; P Newhouse; D Sack; E De Souza; C Sadowsky; E Roberts
Journal:  Neurology       Date:  2003-04-08       Impact factor: 9.910

6.  Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study.

Authors:  P N Wang; S Q Liao; R S Liu; C Y Liu; H T Chao; S R Lu; H Y Yu; S J Wang; H C Liu
Journal:  Neurology       Date:  2000-06-13       Impact factor: 9.910

7.  Childhood-onset growth hormone deficiency, cognitive function and brain N-acetylaspartate.

Authors:  P Sytze van Dam; Channa F de Winter; Rehana de Vries; Jeroen van der Grond; Madeleine L Drent; Marijn Lijffijt; J Leon Kenemans; André Aleman; Edward H F de Haan; Hans P F Koppeschaar
Journal:  Psychoneuroendocrinology       Date:  2005-01-12       Impact factor: 4.905

8.  Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal postmenopausal women.

Authors:  Julie Dumas; Catherine Hancur-Bucci; Magdalena Naylor; Cynthia Sites; Paul Newhouse
Journal:  Neuropsychopharmacology       Date:  2006-02-15       Impact factor: 7.853

9.  The natural history of Alzheimer disease: a longitudinal presymptomatic and symptomatic study of a familial cohort.

Authors:  Alison K Godbolt; Lisa Cipolotti; Hilary Watt; Nick C Fox; John C Janssen; Martin N Rossor
Journal:  Arch Neurol       Date:  2004-11

Review 10.  Potential use of estrogen-like drugs for the prevention of Alzheimer's disease.

Authors:  Jonathan D Smith; Justine A Levin-Allerhand
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866

View more
  2 in total

1.  Proposing a "Brain Health Checkup (BHC)" as a Global Potential "Standard of Care" to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of "Dopamine Homeostasis".

Authors:  Eric R Braverman; Catherine A Dennen; Mark S Gold; Abdalla Bowirrat; Ashim Gupta; David Baron; A Kenison Roy; David E Smith; Jean Lud Cadet; Kenneth Blum
Journal:  Int J Environ Res Public Health       Date:  2022-04-30       Impact factor: 4.614

2.  Effects of differences in serum total homocysteine, folate, and vitamin B12 on cognitive impairment in stroke patients.

Authors:  Bo Jiang; Yumei Chen; Guoen Yao; Cunshan Yao; Hongmei Zhao; Xiangdong Jia; Yunyan Zhang; Junling Ge; Enchao Qiu; Chengyun Ding
Journal:  BMC Neurol       Date:  2014-11-30       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.